OMER - OMEROS CORP
IEX Last Trade
10.38
0.055 0.530%
Share volume: 14,721
Last Updated: Thu 26 Dec 2024 08:30:06 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$10.32
0.06
0.53%
Fundamental analysis
42%
Profitability
45%
Dept financing
26%
Liquidity
75%
Performance
34%
Performance
5 Days
-1.09%
1 Month
-17.70%
3 Months
155.10%
6 Months
161.78%
1 Year
178.55%
2 Year
293.70%
Key data
Stock price
$10.38
DAY RANGE
$9.82 - $10.46
52 WEEK RANGE
$3.04 - $13.60
52 WEEK CHANGE
$184.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Gregory A. Demopulos
Region: US
Website: omeros.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: omeros.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Omeros Corporation discovers, develops, and commercializes small-molecule and protein therapeutics. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and atypical hemolytic uremic syndrome (aHUS) The company was incorporated in 1994 and headquartered in Seattle, Washington.
Recent news